Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer.
NETs biomarkers
dedifferentiated thyroid cancer
neutrophil extracellular traps
neutrophils
thyroid cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
02
2023
accepted:
14
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Polymorphonuclear neutrophils (PMNs) are the main effector cells in inflammatory responses and play multiple roles in thyroid cancer (TC). PMNs contain and release a plethora of mediators, including granular enzymes [e.g., myeloperoxidase (MPO), pentraxin-3 (PTX3) and matrix metalloproteinase-9 (MMP-9)], and neutrophil extracellular traps (NETs). The aim of this study was to evaluate NETs and neutrophil-derived mediators as possible biomarkers in TC patients. 20 patients with differentiated thyroid cancer (DTC), 26 patients with dedifferentiated thyroid cancer (De-DTC), 26 patients with multinodular goiter (MNG) and 22 healthy controls (HCs) were recruited. Serum concentrations of free DNA (dsDNA), nucleosomes, citrullinated histone H3 (CitH3) and MPO-DNA complexes were evaluated as NET biomarkers. Neutrophil-related mediators such as MPO, PTX3, MMP-9, CXCL8, and granulocyte-monocyte colony-stimulating factor (GM-CSF) were measured by ELISA. Serum levels of all four NET biomarkers were increased in DeDTC patients compared to HCs. CitH3 serum levels were selectively increased in both DeDTC and DTC patients compared to HCs and MNG patients. MPO-DNA complexes and nucleosomes were selectively increased only in DeDTC patients compared to HCs and MNG patients. Moreover, MPO-DNA complexes were selectively increased in DeDTC patients compared to DTC patients also. MPO circulating levels were selectively increased in the DeDTC patient subgroup compared to HCs. Circulating levels of PTX3, MMP-9 and GM-CSF were increased in DTC and DeDTC patients compared to HCs. Nucleosomes positively correlated with dsDNA, CitH3, MPO and CXCL8. MPO-DNA complexes positively correlated with dsDNA, CitH3, CXCL8, MPO and nucleosome levels. Moreover, three out of the four NET biomarkers (i.e., dsDNA, nucleosomes and MPO-DNA complexes) were increased in elderly patients compared to young patients and in patients with metastatic disease at diagnosis compared to non metastatic patients. Nucleosomes were higher in males compared to females. MPO-DNA complexes, nucleosomes and, to some extent, CitH3 levels seem to correlate with malignancy and severity of progressive TC. Moreover, serum concentrations of PMN-related mediators (MPO, PTX3, GM-CSF) were increased in TCs compared to MNG and HCs.
Sections du résumé
Background
Polymorphonuclear neutrophils (PMNs) are the main effector cells in inflammatory responses and play multiple roles in thyroid cancer (TC). PMNs contain and release a plethora of mediators, including granular enzymes [e.g., myeloperoxidase (MPO), pentraxin-3 (PTX3) and matrix metalloproteinase-9 (MMP-9)], and neutrophil extracellular traps (NETs). The aim of this study was to evaluate NETs and neutrophil-derived mediators as possible biomarkers in TC patients.
Methods
20 patients with differentiated thyroid cancer (DTC), 26 patients with dedifferentiated thyroid cancer (De-DTC), 26 patients with multinodular goiter (MNG) and 22 healthy controls (HCs) were recruited. Serum concentrations of free DNA (dsDNA), nucleosomes, citrullinated histone H3 (CitH3) and MPO-DNA complexes were evaluated as NET biomarkers. Neutrophil-related mediators such as MPO, PTX3, MMP-9, CXCL8, and granulocyte-monocyte colony-stimulating factor (GM-CSF) were measured by ELISA.
Results
Serum levels of all four NET biomarkers were increased in DeDTC patients compared to HCs. CitH3 serum levels were selectively increased in both DeDTC and DTC patients compared to HCs and MNG patients. MPO-DNA complexes and nucleosomes were selectively increased only in DeDTC patients compared to HCs and MNG patients. Moreover, MPO-DNA complexes were selectively increased in DeDTC patients compared to DTC patients also. MPO circulating levels were selectively increased in the DeDTC patient subgroup compared to HCs. Circulating levels of PTX3, MMP-9 and GM-CSF were increased in DTC and DeDTC patients compared to HCs. Nucleosomes positively correlated with dsDNA, CitH3, MPO and CXCL8. MPO-DNA complexes positively correlated with dsDNA, CitH3, CXCL8, MPO and nucleosome levels. Moreover, three out of the four NET biomarkers (i.e., dsDNA, nucleosomes and MPO-DNA complexes) were increased in elderly patients compared to young patients and in patients with metastatic disease at diagnosis compared to non metastatic patients. Nucleosomes were higher in males compared to females.
Conclusion
MPO-DNA complexes, nucleosomes and, to some extent, CitH3 levels seem to correlate with malignancy and severity of progressive TC. Moreover, serum concentrations of PMN-related mediators (MPO, PTX3, GM-CSF) were increased in TCs compared to MNG and HCs.
Identifiants
pubmed: 37705974
doi: 10.3389/fimmu.2023.1167404
pmc: PMC10495767
doi:
Substances chimiques
Matrix Metalloproteinase 9
EC 3.4.24.35
Nucleosomes
0
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Histones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1167404Informations de copyright
Copyright © 2023 Modestino, Cristinziano, Poto, Ventrici, Trocchia, Ferrari, Fallahi, Paparo, Marone, Antonelli, Varricchi and Galdiero.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Death Dis. 2020 Apr 30;11(4):300
pubmed: 32355207
Immunol Res. 2018 Dec;66(6):710-722
pubmed: 30617967
Blood. 2019 May 16;133(20):2178-2185
pubmed: 30898862
Int J Surg. 2016 Sep;33 Suppl 1:S159-63
pubmed: 27393960
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272
pubmed: 35271818
Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):330-334
pubmed: 30048260
Biomed Pharmacother. 2008 Oct;62(8):559-63
pubmed: 18725177
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
Tissue Eng Regen Med. 2020 Apr;17(2):141-153
pubmed: 32114678
Front Immunol. 2012 Sep 03;3:277
pubmed: 22969769
J Immunol. 2014 Jun 1;192(11):5314-23
pubmed: 24771850
Endocr Relat Cancer. 2009 Dec;16(4):1299-311
pubmed: 19755523
Front Immunol. 2018 Feb 27;9:327
pubmed: 29535718
J Exp Med. 1988 Apr 1;167(4):1364-76
pubmed: 3258625
Thyroid. 2021 Jul;31(7):1041-1049
pubmed: 33487121
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42
pubmed: 32055496
J Surg Res. 2019 Nov;243:189-197
pubmed: 31185435
Cytokine. 2012 Aug;59(2):218-22
pubmed: 22633083
J Exp Med. 2022 Jun 6;219(6):
pubmed: 35522219
BMC Cancer. 2018 Jun 22;18(1):678
pubmed: 29929491
Sci Rep. 2015 Jul 20;5:12287
pubmed: 26192381
Nat Rev Cancer. 2020 Sep;20(9):485-503
pubmed: 32694624
Semin Cancer Biol. 2022 Feb;79:180-196
pubmed: 33249201
Anticancer Res. 2022 Feb;42(2):965-971
pubmed: 35093896
Oncoimmunology. 2016 Mar 30;5(6):e1168556
pubmed: 27471646
J Allergy Clin Immunol. 2020 Jun;145(6):1535-1544
pubmed: 32283205
J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81
pubmed: 24423321
J Immunol. 2011 Jul 1;187(1):538-52
pubmed: 21613614
Curr Opin Immunol. 2012 Dec;24(6):736-9
pubmed: 22981682
Nat Rev Immunol. 2019 Apr;19(4):255-265
pubmed: 30816340
Thyroid. 2015 Oct;25(10):1106-14
pubmed: 26148759
Cytokine Growth Factor Rev. 2013 Dec;24(6):539-46
pubmed: 24011840
Clin Endocrinol (Oxf). 2009 Jun;70(6):946-53
pubmed: 18785992
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Cancer Cell. 2023 Apr 10;41(4):757-775.e10
pubmed: 37037615
Immunol Lett. 2014 Aug;160(2):186-94
pubmed: 24670966
Semin Cancer Biol. 2022 Feb;79:91-104
pubmed: 34280576
Blood. 1992 Dec 1;80(11):2920-4
pubmed: 1280481
BMC Cancer. 2020 Nov 30;20(1):1166
pubmed: 33256657
Immunobiology. 2013 Nov;218(11):1402-10
pubmed: 23891329
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Nat Med. 2018 Feb;24(2):232-238
pubmed: 29309057
Am J Respir Cell Mol Biol. 1992 Nov;7(5):507-13
pubmed: 1384583
Immunity. 2020 May 19;52(5):856-871.e8
pubmed: 32289253
J Intern Med. 2019 May;285(5):524-532
pubmed: 30873708
J Immunol. 2020 Mar 1;204(5):1362-1372
pubmed: 31959732
Nat Med. 2014 May;20(5):511-7
pubmed: 24784231
Sci Rep. 2021 Sep 9;11(1):18025
pubmed: 34504150
J Infect Dis. 2018 Jan 17;217(3):428-437
pubmed: 29325098
J Leukoc Biol. 2012 Mar;91(3):369-76
pubmed: 22131345
Allergy. 2020 Jan;75(1):95-103
pubmed: 31330043
Clin Exp Immunol. 1995 Jul;101 Suppl 1:6-9
pubmed: 7606861
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
Mol Immunol. 2021 May;133:110-121
pubmed: 33640761
Pharmacol Rev. 2010 Dec;62(4):726-59
pubmed: 21079042
Endocr Relat Cancer. 2014 Apr 28;21(3):R85-R103
pubmed: 24302667
PLoS One. 2016 May 02;11(5):e0154484
pubmed: 27136460
J Innate Immun. 2018;10(5-6):414-421
pubmed: 29909412
Semin Cancer Biol. 2020 Aug;64:135-146
pubmed: 31158464
Nat Commun. 2021 May 13;12(1):2776
pubmed: 33986291
Semin Cancer Biol. 2022 Feb;79:203-216
pubmed: 32569821
Oncogene. 2010 Nov 25;29(47):6203-15
pubmed: 20729915
Mol Cancer. 2018 Aug 8;17(1):116
pubmed: 30089490
Aging Cell. 2014 Aug;13(4):690-8
pubmed: 24779584
Nat Med. 2009 Jun;15(6):623-5
pubmed: 19448636
Oncotarget. 2016 Jan 12;7(2):1500-15
pubmed: 26625205
Curr Oncol Rep. 2021 Aug 3;23(10):118
pubmed: 34342735
J Exp Clin Cancer Res. 2022 Apr 21;41(1):151
pubmed: 35449078
PLoS One. 2018 Jun 28;13(6):e0199740
pubmed: 29953504
Cell Death Differ. 2019 Mar;26(3):395-408
pubmed: 30622307